2024-03-28T21:30:09Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:02001158
2023-11-16T02:04:27Z
499:508:509:1624513305190
Early glottic cancer treatment with concurrent chemoradiotherapy with once-daily orally administered S-1
Takase, Yuuki
Itoh, Yoshiyuki
Ohtakara, Kazuhiro
Kawamura, Mariko
Ito, Junji
Oie, Yumi
Ono, Tamami
Sasaki, Yutaro
Nishida, Ayumi
Naganawa, Shinji
early glottic carcinoma
radiation therapy
concurrent chemoradiotherapy
Glottic carcinoma is the most common laryngeal cancer. The outcomes for T1 bulky Glottic carcinoma and T2N0 Glottic carcinoma after radiation therapy alone are unsatisfactory. This study was conducted to evaluate the efficacy and safety of unique concurrent chemoradiotherapy regimen using S-1 for early glottic cancer. Concurrent chemoradiotherapy consisted of 60 Gy in 30 fractions with once-daily, orally administered S-1 exclusively within three to six hours prior to each irradiation. Twenty-one consecutive patients treated with this regimen were retrospectively reviewed. Initial complete remission was achieved in all patients without any subsequent local and/or regional recurrences to the last follow-up. The 4-year local control, overall survival, and disease-free survival rates were all 100%. No significant toxicities were observed, except for three cases with Grade 3 acute dermatitis.This regimen is highly effective and well-tolerated, and these results encourage further research to long-term efficacy and functional preservation.
departmental bulletin paper
Nagoya University Graduate School of Medicine, School of Medicine
2021-05
application/pdf
Nagoya Journal of Medical Science
2
83
251
258
0027-7622
2186-3326
https://nagoya.repo.nii.ac.jp/record/2001158/files/04_Takase.pdf
eng
https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/832.html
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International